Company / Cash & Equivalents
Tango Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$112.3M
FY2025
5-year range
$60.0M / $142.7M
FY2021-FY2025
Trend
+61.5%
vs FY2024
Sector context
#134 of 207
Health Care
What the data says
At $112M, Tango Therapeutics, Inc.'s cash & equivalents ranks #134 of 207 in the Health Care sector. Cash & Equivalents has increased for 3 consecutive years, from $60M in FY2022 to $112M in FY2025.
Based on SEC 10-K filings.
$112M in FY2025 with a 5-year CAGR of +31.7%.
Improved from $66M to $112M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +23.3%
- 5-Year CAGR
- +31.7%
- 10-Year CAGR
- -
Sector benchmark
#134 of 207 in Health CareTop 65% of 207This company $112.3M Sector average $669.5M
▼
-83.2% below sector average
Key checks
Key Insights
- Tango Therapeutics, Inc.'s cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +31.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 61.5% year-over-year.
- Ranks #134 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.3M | +61.5% |
| FY2024 | $69.5M | +4.7% |
| FY2023 | $66.4M | +10.7% |
| FY2022 | $60.0M | -58.0% |
| FY2021 | $142.7M | +403.0% |
| FY2020 | $28.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026